4 news items
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GRTS
9 May 24
therapy in metastatic microsatellite-stable colorectal cancer (MSS-CRC) demonstrated a favorable trend in progression-free survival (PFS). Long-term circulating
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
GRTS
29 Apr 24
and drive long-term value for our shareholders." "Mr. Webster's extensive experience guiding companies through dynamic competitive environments
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
GRTS
1 Apr 24
(as defined by protocol) is uninformative due to an unexpectedly persistent ctDNA drop beyond induction chemotherapy; long-term circulating tumor DNA (ctDNA
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GRTS
5 Mar 24
Long
- Prev
- 1
- Next